22-Apr-2024
Leerink Partners Keeps Their Buy Rating on NeoGenomics (NEO)
TipRanks (Mon, 22-Apr 1:16 AM ET)
NeoGenomics announces senior leadership promotions
Seeking Alpha News (Thu, 18-Apr 7:25 AM ET)
NeoGenomics Announces Executive Team Restructuring and Appointments
TipRanks (Thu, 18-Apr 7:12 AM ET)
NeoGenomics Announces Senior Leadership Promotions
Business Wire (Thu, 18-Apr 7:05 AM ET)
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
Business Wire (Tue, 9-Apr 7:00 AM ET)
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
Business Wire (Wed, 27-Mar 8:30 AM ET)
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
Business Wire (Wed, 20-Mar 7:00 AM ET)
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
Business Wire (Fri, 1-Mar 7:05 AM ET)
NeoGenomics Reports Fourth Quarter and Full Year 2023 Results
Business Wire (Tue, 20-Feb 4:05 PM ET)
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
Business Wire (Thu, 1-Feb 7:05 AM ET)
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
Neogenomics trades on the NASDAQ stock market under the symbol NEO.
As of April 22, 2024, NEO stock price declined to $13.42 with 736,873 million shares trading.
NEO has a beta of 1.75, meaning it tends to be more sensitive to market movements. NEO has a correlation of 0.13 to the broad based SPY ETF.
NEO has a market cap of $1.71 billion. This is considered a Small Cap stock.
Last quarter Neogenomics reported $156 million in Revenue and $.03 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.05.
In the last 3 years, NEO stock traded as high as $54.74 and as low as $6.00.
The top ETF exchange traded funds that NEO belongs to (by Net Assets): IJR, VTI, VB, IWM, VXF.
NEO has underperformed the market in the last year with a price return of -16.1% while the SPY ETF gained +22.9%. NEO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.1% and -9.6%, respectively, while the SPY returned +3.7% and -3.7%, respectively.
NEO support price is $13.18 and resistance is $13.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NEO stock will trade within this expected range on the day.